The study is designed to to assess the efficacy of ablative SBRT delivered with VMAT technique in oligometastatic patients affected by adrenal gland metastases.

This is a phase II, single arm, trial for testing efficacy of ablative high hypofractionated dose delivered with VMAT technique in oligometastatic patients with adrenal gland metastases. The potential advantages of this approach include the possibility to lead an increased local control in irradiated adrenal gland metastases. Other purpose of this study is to assess acute and late toxicity in terms of maintenance of endocrine mechanisms of hormonal production.

Inclusion Criteria:

• Age ≥ 18years.
• WHO performance status ≤ 1 (ECOG - KPS).
• Histologically-proven of primary cancer disease
• Metastases at adrenal gland radiologically proven
• Written informed consent

Exclusion Criteria:

• Prior radiation to the interested adrenal gland.
• Patients allergic to contrast used in CT scans or who cannot be premedicated for the use of contrast.